New challenges for an expanding generation of older persons with haemophilia
Authors
O’Hara, Jamie; orcid: 0000-0001-8262-034XNoone, Declan; orcid: 0000-0003-2183-4277
Kritikou, Persefoni
Myren, Karl-Johan; orcid: 0000-0003-2065-2930
Chaplin, Steve; orcid: 0000-0001-7508-5609
Hart, Daniel P; orcid: 0000-0001-9084-8598
Publication Date
2022-03-09
Metadata
Show full item recordAbstract
Abstract Background Increasing survival among people with haemophilia means that more individuals are at risk of developing age-related morbidity. Little is known about morbidity and health-related quality of life (HRQoL) in different age groups within a single large population of people with haemophilia. Aim This study aimed to explore the association between increasing age and comorbidity among people with haemophilia and to compare their HRQoL with that of a sample of the general population in England. Methods The prevalence of comorbidity recorded in medical records and HRQoL assessed by EQ-5D were compared by age group in participants in the Cost of Haemophilia in Europe: A Socioeconomic Survey study (CHESS) in Europe. HRQoL was compared with that of a sample of the general population taken from the 2012 Health Survey for England (HSE). Results Younger adults in CHESS were more likely to have received prophylaxis from an early age. The mean number of affected joints in younger adults was 1.0; participants aged 41–50 (1.25) and 51–60 years (1.41) had the highest mean number of affected joints. The prevalence of comorbidity was 36% in patients aged 18–30, 61% in 31–60-year-olds and 68% in those aged 61+. HRQoL impairment in young adults with haemophilia was comparable with that in the HSE population aged over 60. Conclusions Older people with haemophilia have impaired quality of life compared with younger adults and an increasing prevalence of several age-related disorders affecting mental health and cardiovascular and bone health. Young adults with haemophilia report impaired HRQoL comparable with that in a general population aged 61+.Citation
The Journal of Haemophilia Practice, volume 9, issue 1, page 1-13Publisher
Walter de Gruyter GmbHType
articleDescription
From Crossref journal articles via Jisc Publications RouterHistory: ppub 2022-01-01, issued 2022-01-01, epub 2022-03-09
Publication status: Published
Collections
Related items
Showing items related by title, author, creator and subject.
-
Publisher Correction: Situational factors shape moral judgements in the trolley dilemma in Eastern, Southern and Western countries in a culturally diverse sample.Bago, Bence; orcid: 0000-0001-6905-1832; Kovacs, Marton; orcid: 0000-0002-8142-8492; Protzko, John; orcid: 0000-0001-5710-8635; Nagy, Tamas; orcid: 0000-0001-5244-0356; Kekecs, Zoltan; orcid: 0000-0001-9247-9781; Palfi, Bence; orcid: 0000-0002-6739-8792; Adamkovic, Matus; Adamus, Sylwia; orcid: 0000-0002-7399-8735; Albalooshi, Sumaya; orcid: 0000-0002-3826-4795; Albayrak-Aydemir, Nihan; orcid: 0000-0003-3412-4311; et al. (2022-06-06)
-
New insights into Perrault syndrome, a clinically and genetically heterogeneous disorder.Faridi, Rabia; orcid: 0000-0001-7788-8755; Rea, Alessandro; orcid: 0000-0002-6204-846X; Fenollar-Ferrer, Cristina; orcid: 0000-0003-4953-8891; O'Keefe, Raymond T; orcid: 0000-0001-8764-1289; Gu, Shoujun; Munir, Zunaira; orcid: 0000-0003-3342-9658; Khan, Asma Ali; orcid: 0000-0002-0894-3439; Riazuddin, Sheikh; orcid: 0000-0001-6012-0192; Hoa, Michael; orcid: 0000-0001-7469-2909; Naz, Sadaf; orcid: 0000-0002-1912-0235; et al. (2021-08-02)Hearing loss and impaired fertility are common human disorders each with multiple genetic causes. Sometimes deafness and impaired fertility, which are the hallmarks of Perrault syndrome, co-occur in a person. Perrault syndrome is inherited as an autosomal recessive disorder characterized by bilateral mild to severe childhood sensorineural hearing loss with variable age of onset in both sexes and ovarian dysfunction in females who have a 46, XX karyotype. Since the initial clinical description of Perrault syndrome 70 years ago, the phenotype of some subjects may additionally involve developmental delay, intellectual deficit and other neurological disabilities, which can vary in severity in part dependent upon the genetic variants and the gene involved. Here, we review the molecular genetics and clinical phenotype of Perrault syndrome and focus on supporting evidence for the eight genes (CLPP, ERAL1, GGPS1, HARS2, HSD17B4, LARS2, RMND1, TWNK) associated with Perrault syndrome. Variants of these eight genes only account for approximately half of the individuals with clinical features of Perrault syndrome where the molecular genetic base remains under investigation. Additional environmental etiologies and novel Perrault disease-associated genes remain to be identified to account for unresolved cases. We also report a new genetic variant of CLPP, computational structural insight about CLPP and single cell RNAseq data for eight reported Perrault syndrome genes suggesting a common cellular pathophysiology for this disorder. Some unanswered questions are raised to kindle future research about Perrault syndrome. [Abstract copyright: © 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.]
-
Risk Governance of Emerging Technologies Demonstrated in Terms of its Applicability to Nanomaterials.Isigonis, Panagiotis; orcid: 0000-0002-8404-7708; Afantitis, Antreas; Antunes, Dalila; Bartonova, Alena; Beitollahi, Ali; Bohmer, Nils; Bouman, Evert; Chaudhry, Qasim; Cimpan, Mihaela Roxana; Cimpan, Emil; et al. (2020-07-23)Nanotechnologies have reached maturity and market penetration that require nano-specific changes in legislation and harmonization among legislation domains, such as the amendments to REACH for nanomaterials (NMs) which came into force in 2020. Thus, an assessment of the components and regulatory boundaries of NMs risk governance is timely, alongside related methods and tools, as part of the global efforts to optimise nanosafety and integrate it into product design processes, via Safe(r)-by-Design (SbD) concepts. This paper provides an overview of the state-of-the-art regarding risk governance of NMs and lays out the theoretical basis for the development and implementation of an effective, trustworthy and transparent risk governance framework for NMs. The proposed framework enables continuous integration of the evolving state of the science, leverages best practice from contiguous disciplines and facilitates responsive re-thinking of nanosafety governance to meet future needs. To achieve and operationalise such framework, a science-based Risk Governance Council (RGC) for NMs is being developed. The framework will provide a toolkit for independent NMs' risk governance and integrates needs and views of stakeholders. An extension of this framework to relevant advanced materials and emerging technologies is also envisaged, in view of future foundations of risk research in Europe and globally. [Abstract copyright: © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.]